The combined Group, named 3PBIOVIAN, will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for Drug Substance and Drug Pr...
Read moreLa empresa recibe el premio a la Mejor Trayectoria Viveros CEIN en el Congreso Internacional de Emprendimiento de Alto Impacto
Read more3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological drugs advances its internatio...
Read more3P Biopharmaceuticals and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished the process transfer and GMP supply of FGF-1 candidate.
Read more3P Biopharmaceuticals and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished the process transfer and GMP supply of FGF-1 candidate.
Read more3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological products has a 68% female wor...
Read more3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of biological products, recently awarded the...
Read more3P Biopharmaceuticals incorporates a new member to the executive management team by engaging Diego Bochoeyer as Director of Strategic Development and Supply Chain.
Read more3P Biopharmaceuticals and Precirix NV have signed an agreement for the clinical manufacturing of a camelid single-domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to...
Read more3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.
Read more3P se ocupará de la fabricación cGMP de Isunakinra, un medicamento contra tumores sólidos, que se encuentra en fase I/II de desarrollo en pacientes en EEUU
Read moreLas empresas biotecnológicas Invizius y 3P Biopharmaceuticals colaboran en una tecnología innovadora para los pacientes que se someten a hemodiálisis y sufren de enfermedades cardiovasculares
Read more